What the FDA labels say about taking them together
Cisplatin and tacrolimus
Tacrolimus's FDA label of July 17, 2026 names cisplatin in its warnings and precautions section; the cisplatin label PlainMeds reads does not name tacrolimus. The tacrolimus label: “The risk for nephrotoxicity may increase when PROGRAF is concomitantly administered with CYP3A inhibitors or drugs associated with nephrotoxicity.”
Check it at the source: the cisplatin FDA label on DailyMed (effective September 16, 2021, WG Critical Care, LLC); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the cisplatin label say about tacrolimus?
Cisplatin's label (effective September 16, 2021) does not name tacrolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (CISplatin), NDA018057 (Hq Spclt Pharma), as published by WG Critical Care, LLC, effective September 16, 2021 (SPL set 2bf8d2fb-80c8-401d-8e9b-d58463f5e954), via openFDA; the full label on DailyMed
What does the tacrolimus label say about cisplatin?
Tacrolimus label, warnings and precautionsThe risk for nephrotoxicity may increase when tacrolimus is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors).
Astagraf Xl label (Astellas Pharma US, Inc., January 14, 2026), warnings and precautionsThe risk for nephrotoxicity may increase when ASTAGRAF XL is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors).
Source: FDA drug label (Prograf, NDA050708), Astellas Pharma US, Inc., effective August 25, 2023 (SPL set 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b), via openFDA
Source: FDA drug label (Astagraf Xl, NDA204096), Astellas Pharma US, Inc., effective January 14, 2026 (SPL set 550a5cd4-fbf2-4c09-b577-6bde8fcbdf6e), via openFDA
Source: FDA drug label (Envarsus Xr, NDA206406), Veloxis Pharmaceuticals, Inc, effective February 26, 2025 (SPL set de2315b0-6344-43ac-9aea-3e3b68d828e7), via openFDA
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cisplatin | Tacrolimus | |
|---|---|---|
| Labeled for | n/a | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.970 per gram 0.1% ointment |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once